Akèy › Maladi otoim › Texas › Houston
Etid klinik pou Maladi otoim nan Houston, TX
21 etid pou Maladi otoim ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Ap rekriteFaz 3
- Abigail Neiman MD PA, Houston
- Novel Research LLC, Bellaire · 7 mi lwen
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Ap rekriteFaz 2
- Jade Clinical Site, Houston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Baylor College of Medicine, Houston
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Ap rekriteFaz 2/3
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Ap rekriteFaz 2
- University of Texas - Houston, Houston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Baylor College of Medicine, Houston
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Ap rekriteFaz 3
- GSK Investigational Site, Houston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Ap rekriteFaz 3
- Nephro Asso North Illinois Indiana, Houston
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Ap rekriteFaz 1/2
- Baylor College of Medicine Neurology Department, Houston
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Ap rekriteFaz 3
- Texas Children's Hospital/ Baylor College of Medicine, Houston
Study of BHV-1300 in Graves' Disease
Ap rekriteFaz 1
- Site-106, Houston
- Site-101, Houston
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Ap rekriteFaz 3
- Site Number - 1057, Houston
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Ap rekriteFaz 2/3
- Houston Methodist Hospital, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Ap rekriteFaz 1/2
- MD Anderson Texas Medical Center, Houston
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Ap rekriteFaz 1
- Houston Methodist Hospital, Houston
Etid Maladi otoim nan lòt vil
- Washington, DC19 etid
- New York City, NY19 etid
- Philadelphia, PA16 etid
- Durham, NC15 etid
- Boston, MA13 etid
- Los Angeles, CA12 etid
- Chicago, IL12 etid
- Dallas, TX9 etid
- Cleveland, OH8 etid
- Milwaukee, WI8 etid
- Atlanta, GA8 etid
- Portland, OR8 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.